Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy

PD-1/PD-L1 inhibitors are a group of immune checkpoint inhibitors as front-line treatment of multiple types of cancer. However, the serious immune-related adverse reactions limited the clinical application of PD-1/PD-L1 monoclonal antibodies, despite the promising curative effects. Therefore, it is...

Descripción completa

Detalles Bibliográficos
Autores principales: Ai, Leilei, Chen, Jian, Yan, Hao, He, Qiaojun, Luo, Peihua, Xu, Zhifei, Yang, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490077/
https://www.ncbi.nlm.nih.gov/pubmed/32982171
http://dx.doi.org/10.2147/DDDT.S267433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490077/
https://www.ncbi.nlm.nih.gov/pubmed/32982171
http://dx.doi.org/10.2147/DDDT.S267433

Ejemplares similares